1. Song KE, Kim DJ, Park JW, Cho HK, Lee KW, Huh KB. Clinical characteristics of Korean type 2 diabetic patients according to insulin secretion and insulin resistance. J Korean Diabetes Assoc. 2007. 31:123–129.

2. Park MN, Kang YI, Chon S, Oh SJ, Woo JT, Kim SW, Kim JW, Kim YS. The clinical characteristics of young onset diabetes according to etiology based classification. J Korean Diabetes Assoc. 2006. 30:190–197.

3. Lee HC, Kim DH, Nam JH, Ahn CW, Lim SK, Huh KB, Nam SY, Park SW, Song YD, Kim HS, Kweon JW, Chang KH, Kim KR. Follow-up study of clinical and immunogenetic characteristics and basal C-peptide in Korea young age onset diabetic patients. J Korean Diabetes Assoc. 1999. 23:288–298.

4. Ko KS, Hong SK, Lee KU, Kim NH, Choi DS, Ihm SH, Park SW, Kim CH, Byun DW, Suh KI, Chang HC, Rhee BD. The frequency of ICA and anti - GAD antibody in Korean IDDM and NIDDM patients. J Korean Diabetes Assoc. 1998. 22:312–319.

5. Kim CS, Park JA, Cho MH, Park JS, Nam JY, Kim DM, Ahn CW, Cha BS, Lim SK, Kim KR, Lee HC. The frequency of anti-GAD antibody in non-obese, adult-onset type 2 diabetes in Korea and clinical and biological characteristics according to anti-GAD antibody. J Korean Diabetes Assoc. 2004. 28:66–74.

6. Park YS. The significance of anti-GAD antibodies in lean patients with type 2 diabetes mellitus. J Korean Diabetes Assoc. 2004. 28:63–65.

7. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoantibodies to islet cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes study (UKPDS) Group. Lancet. 1997. 350:1288–1293.

8. Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet β-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract. 2009. 83:54–60.

9. Maruyama T, Shimada A, Oak S, Hampe CS. GAD65 autoantibody responses in Japanese latent autoimmune diabetes in adult patients. Diabetes Care. 2008. 31:1602–1607.

10. Jun HS, Khil LY, Yoon JW. Role of glutamic acid decarboxylase in the pathogenesis of type 1 diabetes. Cell Mol Life Sci. 2002. 59:1892–1901.

11. Leslie RDG, Atkinson MA, Notkins AL. Autoantigens IA-2 GAD in type I (insulin-dependent) diabetes. Diabetologia. 1999. 42:3–14.

12. Baekkeskov S, Nielson JH, Marner B, Bilde T, Ludvigsson J, Lernmark A. Autoantibodies in newly diagnosed diabetic children immunoprecipitate specific human islet cell proteins. Nature. 1982. 298:167–169.

13. Baekkeskov S, Landin M, Kristensen JK, Srikanta S, Bruining GJ, Mandrup-poulsen T. Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes. J Clin Invest. 1987. 79:926–934.

14. Baekkeskov S, Jan-Aanstoot H, Christgau S, Reetz A, Solimena M, Cascalho F. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 1990. 347:151–156.

15. Lee SA, Kim EY, Kim EH, Jeong JY, Jeong EH, Kim DW, Cho EH, Koh EH, Kim MS, Park JY, Lee KU. Anti-GAD Antibody in Patients with Adult-Onset Diabetes in Korea. Korean Diabetes J. 2009. 33:16–23.

16. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes. 1999. 48:108–110.

17. Oh JH, Yoon JS, Won KC, Lee HW. Antibodies to GAD and ICA in type 2 DM with secondary failure of oral hypoglycemic therapy. J Korean Diabetes Assoc. 2007. 31:402–409.

18. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L. Activation of human T lymphocytes isinhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma coassociation with transcription factor NFAT. J Biol Chem. 2000. 275:4541–4544.

19. Wang P, Anderson PO, Chen S, Paulsson KM, Sjogren HO, Li S. Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator activated receptor gamma ligands. Int Immunopharmacol. 2001. 1:803–812.